

Product Name: Ebrotidine Revision Date: 01/10/2020

Product Data Sheet

Ebrotidine

Cat. No.: A3380


CAS No.: 100981-43-9

Formula: C14H17BrN6O2S3

M.Wt: 477.42

Synonyms: FI 3542;Ulsanic;FI-3542;FI3542

Target: Neuroscience
Pathway: Histamine
Storage: Store at -20°C



Solvent & Solubility

Soluble in DMSO

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	2.0946 mL	10.4730 mL	20.9459 mL
	5 mM	0.4189 mL	2.0946 mL	4.1892 mL
	10 mM	0.2095 mL	1.0473 mL	2.0946 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	H2-receptor antagonist,competitive		
IC ₅₀ & Target			
	Cell Viability Assay		
	Cell Line:	Helicobacter. pylori	
	Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining	

In Vitro

Cell Line:	Helicobacter. pylori	
Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining	
	a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or	
	shake it in the ultrasonic bath for a while.Stock solution can be stored below	
	-20°C for several months.	
Reacting conditions:	MIC: 75 micrograms/ml, 5 days	
Applications:	Ebrotidine gave a mean MIC value of 75 micrograms/ml. Ebrotidine at 100	

		micrograms/ml enhanced the activity of the antimicrobials studied as follows: erythromycin 3 times, tetracycline 1.1 times, amoxicillin 3 times, metronidazole-sensitive strains 9 times and clarithromycin 5 times.	
	Animal experiment		
In Vivo	Animal models:	Sprague-Dawley rats with chronic gastric ulcers	
	Dosage form:	Intragastric route100 mg/kg, twice daily for 14 days	
	Applications:	Treatment with ebrotidine resulted in an accelerated ulcer healing. A 40% decrease in ulcer area was observed by the third day and a 71% decrease by the fifth day; the ulcers were essentially healed by the seventh day.	
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may	
		slightly differ with the theoretical value. This is caused by an experimental	
		system error and it is normal.	

Product Citations

See more customer validations on www.apexbt.com.

References

[1] Palacin C, Tarrago C, Sacristan A, et al. In vitro anti-Helicobacter pylori activity of ebrotidine. Arzneimittel-Forschung, 1997, 47(4A): 471-474.

[2] Slomiany B L, Piotrowski J, Slomiany A. Cell cycle progression during gastric ulcer healing by ebrotidine and sucralfate. General Pharmacology: The Vascular System, 1997, 29(3): 367-370.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

